# Bruker to acquire majority stake in Hain Lifescience GmbH

Bruker Corporation has signed a definitive agreement to acquire an 80% majority interest in Hain Lifescience GmbH, a German molecular diagnostics company specializing in infectious disease testing. The acquisition is expected to close in Q4 2018. Financial details were not disclosed.

- Type: Acquisition
- Announced: 2018-08-24
- Where: Nehren, Germany, Germany
- Status: announced
- Products: molecular diagnostics for infectious diseases, tuberculosis testing, STD testing, HIV viral load testing
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Bruker Corporation](https://endata.com/companies/19227.md) (acquirer)
- [Hain Lifescience GmbH](https://endata.com/companies/33916.md) (target)

## Sources

- [biospace.com](https://www.biospace.com/bruker-announces-agreement-to-acquire-majority-in-infectious-disease-focused-molecular-diagnostics-mdx-company-hain-lifescience-gmbh), 2018-08-24: "Bruker expects to acquire an 80% majority interest in Hain, with options for the remaining 20% that can be exercised after 2021."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.